Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Ocular Tolerance of Bacillus Calmette-Guerin Organisms

Ocular Tolerance of Bacillus Calmette-Guerin Organisms Abstract • The results of this investigation indicate that 5 x 106 and 5 x 108 viable bacillus Calmette-Guerin (BCG) organisms (Mycobacterium bovis strain) can be safely administered in the subconjunctival region of the eye of New Zealand albino rabbits without producing toxic effects locally or within the eye. This study provides a format for testing the applicability of BCG immunotherapy for experimental melanomas. (Arch Ophthalmol 95:2210-2213, 1977) References 1. Morton DL, Holmes EC, Eilber FR, et al: Immunological aspects of neoplasia: A rational basis for immunotherapy . Ann Intern Med 74:587-604, 1971.Crossref 2. Holterman OA, Casale GP, Klein E: Tumor cell destruction by macrophages . J Med (Basel) 3:305-309, 1972. 3. Ikonoplsov RL: The rationale of immunostimulation procedures in the therapeutic approach to malignant melanoma of the skin . Tumori 58:121-127, 1972. 4. Alexander P: Activated macrophages and the antitumor action of BCG . Natl Cancer Inst Monogr 39:127-133, 1973. 5. Gutterman J, Mavligit G, McBride C, et al: BCG stimulation of immune responsiveness in patients with malignant melanoma . Cancer 32:321-327, 1973.Crossref 6. Mitchell MS, Kirkpatrick D, Mokyr MB, et al: On the mode of action of BCG . Nature (New Biol) 243:216-218, 1973.Crossref 7. Baldwin RW, Pimm MV: BCG immunotherapy of rat tumors of defined immunogenicity . Natl Cancer Inst Monogr 39:11-17, 1973. 8. Klein E, Holtermann OA, Papermaster B, et al: Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives . Natl Cancer Inst Monogr 39:229-239, 1973. 9. Zbar B: Tumor regression mediated by Mycobacterium bovis (strain BCG) . Natl Cancer Inst Monogr 35:341-344, 1972. 10. Mathé G, Halle-Pannenko O, Bourut C: BCG in cancer immunotherapy: Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy . Natl Cancer Inst Monogr 39:107-112, 1973. 11. Morton DL, Eilber FR, Malmgren RA, et al: Immunological factors which influence response to malignant melanoma . Surgery 68:158-164, 1970. 12. Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG . Cancer Chemother Rep 56:659-665, 1972. 13. Sigler HF, Shingleton WW, Metzgar RS, et al: Nonspecific and specific immunotherapy in patients with melanoma . Surgery 72:162-174, 1972. 14. Pinsky CM, Hirshaut Y, Oettgen HF: Treatment of malignant melanoma by intratumoral injection of BCG . Natl Cancer Inst Monogr 39:225-228, 1973. 15. Eilber FR, Moroon DL, Holmes EC, et al: Immunotherapy with BCG for lymph-node metastases from malignant melanoma . N Engl J Med 294:237-241, 1976.Crossref 16. Rosenthal SR: Focal and general tissue responses to an avirulent tubercle bacillus (BCG) . Arch Pathol 22:348-361, 1936. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

Ocular Tolerance of Bacillus Calmette-Guerin Organisms

Download PDF
4 pages

Loading next page...
 
/lp/american-medical-association/ocular-tolerance-of-bacillus-calmette-guerin-organisms-u9u1wO7hw0

References (19)

Publisher
American Medical Association
Copyright
Copyright © 1977 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1977.04450120116016
Publisher site
See Article on Publisher Site

Abstract

Abstract • The results of this investigation indicate that 5 x 106 and 5 x 108 viable bacillus Calmette-Guerin (BCG) organisms (Mycobacterium bovis strain) can be safely administered in the subconjunctival region of the eye of New Zealand albino rabbits without producing toxic effects locally or within the eye. This study provides a format for testing the applicability of BCG immunotherapy for experimental melanomas. (Arch Ophthalmol 95:2210-2213, 1977) References 1. Morton DL, Holmes EC, Eilber FR, et al: Immunological aspects of neoplasia: A rational basis for immunotherapy . Ann Intern Med 74:587-604, 1971.Crossref 2. Holterman OA, Casale GP, Klein E: Tumor cell destruction by macrophages . J Med (Basel) 3:305-309, 1972. 3. Ikonoplsov RL: The rationale of immunostimulation procedures in the therapeutic approach to malignant melanoma of the skin . Tumori 58:121-127, 1972. 4. Alexander P: Activated macrophages and the antitumor action of BCG . Natl Cancer Inst Monogr 39:127-133, 1973. 5. Gutterman J, Mavligit G, McBride C, et al: BCG stimulation of immune responsiveness in patients with malignant melanoma . Cancer 32:321-327, 1973.Crossref 6. Mitchell MS, Kirkpatrick D, Mokyr MB, et al: On the mode of action of BCG . Nature (New Biol) 243:216-218, 1973.Crossref 7. Baldwin RW, Pimm MV: BCG immunotherapy of rat tumors of defined immunogenicity . Natl Cancer Inst Monogr 39:11-17, 1973. 8. Klein E, Holtermann OA, Papermaster B, et al: Immunologic approaches to various types of cancer with the use of BCG and purified protein derivatives . Natl Cancer Inst Monogr 39:229-239, 1973. 9. Zbar B: Tumor regression mediated by Mycobacterium bovis (strain BCG) . Natl Cancer Inst Monogr 35:341-344, 1972. 10. Mathé G, Halle-Pannenko O, Bourut C: BCG in cancer immunotherapy: Results obtained with various BCG preparations in a screening study for systemic adjuvants applicable to cancer immunoprophylaxis or immunotherapy . Natl Cancer Inst Monogr 39:107-112, 1973. 11. Morton DL, Eilber FR, Malmgren RA, et al: Immunological factors which influence response to malignant melanoma . Surgery 68:158-164, 1970. 12. Nathanson L: Regression of intradermal malignant melanoma after intralesional injection of Mycobacterium bovis strain BCG . Cancer Chemother Rep 56:659-665, 1972. 13. Sigler HF, Shingleton WW, Metzgar RS, et al: Nonspecific and specific immunotherapy in patients with melanoma . Surgery 72:162-174, 1972. 14. Pinsky CM, Hirshaut Y, Oettgen HF: Treatment of malignant melanoma by intratumoral injection of BCG . Natl Cancer Inst Monogr 39:225-228, 1973. 15. Eilber FR, Moroon DL, Holmes EC, et al: Immunotherapy with BCG for lymph-node metastases from malignant melanoma . N Engl J Med 294:237-241, 1976.Crossref 16. Rosenthal SR: Focal and general tissue responses to an avirulent tubercle bacillus (BCG) . Arch Pathol 22:348-361, 1936.

Journal

Archives of Ophthalmology – American Medical Association

Published: Dec 1, 1977

There are no references for this article.